Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight ...

The researchers suggest that sleep deprivation may exacerbate the inflammatory state associated with obesity by increasing ...

A groundbreaking new study has unveiled a dietary approach that significantly reduces the risk of obesity-related cancers — ...

It’s time to treat obesity as a chronic disease and have Medicare cover these life-changing AOMs. By taking action now, we ...

Higher adherence to the Mediterranean diet reduced the risk of obesity-related cancers, but not in the way researchers ...

Welcoming a newborn is something many couples dream of doing, but it can get complicated when conceiving becomes a roadblock.

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...

The state superintendent wants to increase organic food in school meals to fight the rising numbers of childhood obesity and ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...